Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1009-1021 , December 2008

Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer

  • Furio Pacini, MD (Professor of Endocrinology, and Director, Section of Endocrinology and Metabolism, University of Siena, Italy)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39 0577585406; Fax: +39 0577586187.
    • ,
  • Maria Grazia Castagna, MD (Staff Physician, Section of Endocrinology, University Hospital of Siena, Italy)

References 

  1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. Journal of the American Medical Association. 2006;295:2164–2167
  2. Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. European Journal of Endocrinology. 2004;150:133–139
  3. Levi F, Randimbison L, Te VC, et al. Thyroid cancer in Vaud, Switzerland: an update. Thyroid. 2002;12:163–168
  4. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 2001;86:1447–1463
  5. Pacini F, Schlumberger M, Dralle H, et al., European Thyroid Cancer Taskforce  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology. 2006;154:787–803
  6. Cooper DS, Doherty GM, Haugen BR, et al., The American Thyroid Association Guidelines Taskforce  The American Thyroid Association Guidelines Taskforce Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–142
  7. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New England Journal of Medicine. 1998;338:297–306
  8. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine. 1994;97:418–428
  9. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55:794–804
  10. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinology and Metabolism Clinics of North America. 1990;19:685–718
  11. Ozata M, Suzuki S, Miyamoto T, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 1994;79:98–105
  12. Schlumberger M, Baudin . Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. European Journal of Endocrinology. 1998;138:249–252
  13. Pacini F, Lari R, Mazzeo S, et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clinical Endocrinology. 1985;23:405–411
  14. Pacini F, Pinchera A, Giani C, et al. Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clinical Endocrinology. 1980;13:107–110
  15. Spencer CA, LoPresti JS, Fatemi S, et al. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9:435–441
  16. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613–619
  17. Robbins J. Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid. 1999;9:451–453
  18. Guimaraes V, DeGroot LJ. Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid. 1996;6:69–73
  19. Thotakura NR, Desai RK, Bates LG, et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology. 1991;128:341–348
  20. Szkudlinski MW, Thotakura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology. 1993;133:1490–1503
  21. Kashiwai T, Ichihara K, Endo Y, et al. Immunological and biological characteristics of recombinant human thyrotropin. Journal of Immunological Methods. 1991;143:25–30
  22. Weintraub BD, Szkudlinski MW. Development and in vitro characterization of human recombinant thyrotropin. Thyroid. 1999;9:447–450
  23. Huber GK, Fong P, Concepcion ES, et al. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. Journal of Clinical Endocrinology and Metabolism. 1991;72:1328–1331
  24. Cole ES, Lee K, Lauziere K, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (N Y). 1993;11:1014–1024
  25. Colzani RM, Alex S, Fang SL, et al. The effect of recombinant human thyrotropin (rhTSH) on thyroid function in mice and rats. Thyroid. 1998;8:797–801
  26. Ramirez L, Braverman LE, White B, et al. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. Journal of Clinical Endocrinology and Metabolism. 1997;82:2836–2839
  27. Torres MS, Ramirez L, Simkin PH, et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. Journal of Clinical Endocrinology and Metabolism. 2001;86:1660–1664
  28. Lawrence JE, Emerson CH, Sullaway SL, et al. The effect of recombinant human TSH on the thyroid (123)I uptake in iodide treated normal subjects. Journal of Clinical Endocrinology and Metabolism. 2001;86:437–440
  29. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). Journal of Clinical Endocrinology and Metabolism. 1994;78:188–196
  30. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine. 1997;337:888–896
  31. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism. 1999;84:3877–3885
  32. Mariani G, Ferdeghini M, Augeri C, et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biotherapy & Radiopharmaceuticals. 2000;15:211–217
  33. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2001;86:619–625
  34. David A, Blotta A, Bondanelli M, et al. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. Journal of Nuclear Medicine. 2001;42:1470–1475
  35. Vitale G, Lupoli GA, Ciccarelli A, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clinical Endocrinology. 2002;56:247–252
  36. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2001;86:5686–5690
  37. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2003;88:3668–3673
  38. Cailleux AF, Baudin E, Travagli JP, et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. Journal of Clinical Endocrinology and Metabolism. 2000;85:175–178
  39. Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. Journal of Clinical Endocrinology and Metabolism. 2002;87:1499–1501
  40. Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. Journal of Clinical Endocrinology and Metabolism. 2006;91:60–63
  41. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. Journal of Clinical Endocrinology and Metabolism. 2002;87:1490–1498
  42. Mazzaferri EL, Kloos RT. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. Journal of Clinical Endocrinology and Metabolism. 2005;90:5047–5057
  43. Frasoldati A, Pesenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;1(97):90–96
  44. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice. Endocrinology & Metabolism. 2005;1:32–40
  45. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. Journal of Clinical Endocrinology and Metabolism. 2008;9376–9381
  46. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 2004;89:3668–3676
  47. Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology. 2005;153:651–659
  48. Haugen BR. Initial treatment of differentiated thyroid carcinoma. Reviews in Endocrine & Metabolic Disorders. 2000;1:139–145
  49. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001;11:865–869
  50. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism. 2002;87:4063–4068
  51. Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nuclear Medicine Communications. 2006;27:627–632
  52. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology. 2006;1:926–932
  53. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50mCi) and 3700MBq (100mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 2007;92:3542–3546
  54. Sisson JC, Shulkin BL, Lawson S. Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. Journal of Nuclear Medicine. 2003;44:898–903
  55. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:1371–1377
  56. Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine. 2006;47:648–654
  57. Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal of Surgery. 1994;18:600–604
  58. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. Journal of Clinical Endocrinology and Metabolism. 2001;86:4092–4097
  59. Reiners C, Farahati J. 131I therapy of thyroid cancer patients. Quarterly Journal of Nuclear Medicine. 1999;43:324–335
  60. Schlumberger M, Pacini F. Thyroid tumors. 5 edn. Paris: editions Nuclèon; 2003;pp 3–317
  61. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism. 2006;91:2892–2899
  62. Robbins RJ, Driedger A, Magner J, U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group . Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16:1121–1130
  63. Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 2000;85:3640–3645
  64. Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. European Journal of Endocrinology. 2001;144:5–11
  65. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:1077–1086
  66. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer. 2005;12:49–64
  67. Luster M, Felbinger R, Dietlein M, et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15:1147–1155
  68. Mernagh P, Campbell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. European Journal of Endocrinology. 2005;155:405–414

PII: S1521-690X(08)00111-5

doi: 10.1016/j.beem.2008.09.014

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 1009-1021 , December 2008

Article Tools

* Image Usage & Resolution